Clinical trials
Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) clinical trials
Below are recruiting pulmonary arterial hypertension (pah) (who group 1 ph) clinical trials, each written for real people, not researchers. We’re tracking 28 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07481981RecruitingPhase 3
Study of once-daily inhaled TPIP for pulmonary arterial hypertension
This trial tests an inhaled medication (TPIP) that opens blood vessels in the lungs to help you breathe easier and be more active. It is for people with PAH who are already on stable treatment and have moderate symptoms.
Santa Barbara, CaliforniaAges 18–75 - NCT07318597RecruitingPhase 2
A study of an experimental drug for pulmonary arterial hypertension
This trial tests a new medication called REGN13335 for people with pulmonary arterial hypertension (PAH). It aims to see if the drug can improve symptoms and function compared to standard care alone.
Aurora, ColoradoAges 18 years+ - NCT07132788Recruiting
How PAH affects muscle mass
This study looks at how pulmonary arterial hypertension (PAH) impacts lean muscle mass. It may help researchers understand changes in your body and find new ways to support your health.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07214376Recruiting
Nerve ablation for pulmonary hypertension from left heart disease
This trial tests a device that uses a catheter to deliver energy to nerves around the pulmonary arteries, aiming to reduce high blood pressure in the lungs caused by left heart failure. It is for people with ongoing heart failure symptoms despite optimal medications.
Tucson, ArizonaAges 18–85 - NCT07768644Recruiting
Nailfold microscope study for pulmonary hypertension
This study uses a special microscope to look at the tiny blood vessels at the base of your fingernails. It aims to see if these vessels can help doctors understand and monitor pulmonary hypertension, a condition of high blood pressure in the lungs.
Clydebank, West DunbartonshireAges 18 years+ - NCT07143448RecruitingPhase 1/Phase 2
Study of HS235 for pulmonary arterial hypertension in adults
This trial tests an experimental drug called HS235 for people with pulmonary arterial hypertension (PAH), a condition of high blood pressure in the lungs. It aims to see if the drug can help improve symptoms and exercise ability.
Tampa, FloridaAges 18 years+ - NCT07234032RecruitingPhase 3
Long-term follow-up study of TPIP for PH-ILD
This trial is a long-term follow-up study for people who already completed a previous study of an inhaled treprostinil medication (TPIP) for pulmonary hypertension caused by interstitial lung disease (PH-ILD). It tests whether continued treatment with TPIP is safe and effective over a longer period.
Naples, FloridaAges 18 years+ - NCT04991454RecruitingPhase 2
Xenon mri to image lung blood flow in pulmonary hypertension
This trial uses a special MRI scan with xenon gas to take detailed images of how blood moves through your lungs. It aims to see if this imaging can help doctors better understand and manage pulmonary hypertension, which is high blood pressure in the lungs.
Durham, North CarolinaAges 18–75 - NCT07175038RecruitingPhase 2
Study of a new pill for pulmonary hypertension
This study tests a new pill, ROC-101, for people with pulmonary hypertension (high blood pressure in the lungs). It aims to see if the pill can improve symptoms and daily function.
Phoenix, ArizonaAges 18–80 - NCT04062565RecruitingPhase 3
Testing treprostinil plus riociguat for advanced pulmonary artery hypertension
This study tests whether taking injected treprostinil together with riociguat can improve how the heart and lung blood vessels work in people with advanced pulmonary artery hypertension (PAH). It may help improve blood-flow measurements and the structure of the heart.
Tucson, ArizonaAges 18 years+ - NCT04778046RecruitingPhase 2
Study lung pressure treatment for people waiting for transplant
This Phase 2 trial is for adults with pulmonary hypertension who are on the lung transplant waiting list at Duke. It aims to test whether the study treatment can improve lung pressure and related health outcomes, while using things like MRI to monitor changes.
Durham, North CarolinaAges 18 years+ - NCT06350032RecruitingPhase 3
Testing treprostinil safety in children with PAH
This trial tests a medicine called treprostinil in children with severe pulmonary arterial hypertension (high blood pressure in the lungs). The study aims to see if it is safe and tolerable for kids who need this kind of therapy.
Vienna, State of ViennaAges Up to 18 years - NCT06351345RecruitingPhase 2
Xenon imaging study for pulmonary hypertension patients on sotatercept
This trial uses a special imaging technique (xenon MRI) to see how well the lungs are functioning in people with pulmonary arterial hypertension (PAH) who are being treated with the drug sotatercept. It aims to understand if the drug improves lung function.
Durham, North CarolinaAges 18–75 - NCT06549452Recruiting
Mobile health app to help teens with pulmonary hypertension exercise
This trial tests whether a smartphone app can help adolescents with pulmonary hypertension stay active and improve their health. If you are a teen with stable PH and can use an activity tracker, this study may be a good fit.
Nashville, TennesseeAges 10–21 - NCT07013149Recruiting
Switching PAH medicines: does it change your risk?
This study looks at how changing from one PAH medicine (ambrisentan) to another (bosentan) affects your disease risk over time. It compares people who made the switch to those who stayed on ambrisentan.
São Paulo, São PauloAges 18 years+ - NCT06850792Recruiting
Improving treatment adherence with telemedicine and guidance
This study tests whether regular remote check-ins and guidance can help people with pulmonary arterial hypertension stick to their treatment plan. You would be followed by phone or video from University of Sao Paulo.
São Paulo, São PauloAges 18 years+ - NCT06941441RecruitingPhase 3
Exercise and medicine study for pulmonary arterial hypertension
This trial tests whether adding the study drug sotatercept to your current PAH therapy along with a home exercise program can help you feel better and be more active. It's for people with certain types of PAH who are stable on their current treatment.
Seattle, WashingtonAges 18 years+ - NCT06968962Recruiting
Starting PAH treatment: one drug first or two drugs together?
This study compares starting with one medication versus two medications together for people with pulmonary arterial hypertension (PAH). It aims to find out which approach works better for low- or intermediate-risk patients.
Hangzhou, ZhejiangAges 18–80 - NCT06998329Recruiting
PAH diagnosis timing study
This study looks at the timing between first symptoms and diagnosis of pulmonary arterial hypertension (PAH). It aims to better understand how quickly patients get diagnosed after symptoms appear.
São Paulo, São PauloAges 18 years+ - NCT07120789Recruiting
Understanding pulmonary hypertension knowledge questionnaire
This study aims to validate a questionnaire that measures how well patients understand pulmonary hypertension. If you have been diagnosed with Group 1 Pulmonary Arterial Hypertension (PAH) and can read the questionnaire, you may be able to help researchers make sure it's a useful tool.
São Paulo, São PauloAges 18 years+ - NCT07217522Recruiting
Genetics of pulmonary hypertension study
This study looks at the genes that may be linked to pulmonary hypertension. By providing a saliva sample and filling out a health survey from home, you can help researchers learn more about this condition.
Piscataway, New JerseyAges 18 years+ - NCT01712620RecruitingPhase 2
Spironolactone for pulmonary arterial hypertension in stable patients
This trial studies whether spironolactone can improve pulmonary arterial hypertension, a disease that makes the blood vessels in the lungs work too hard. You may be eligible if your condition is confirmed by specific heart-lung pressure tests and your medication plan has been stable for at least 4 weeks.
Bethesda, MarylandAges 18–100 - NCT01730092Recruiting
Study of blood and imaging biomarkers in pulmonary artery hypertension
This study tracks natural changes in “biomarkers” (measurable signals in blood) and imaging findings in people with pulmonary arterial hypertension (PAH) or suspected PAH. It also includes healthy people for comparison, helping researchers understand what these signals mean over time.
Bethesda, MarylandAges 18–100 - NCT01347216Recruiting
COMPERA study for lung vessel pressure medicines
This study follows people with different types of high blood pressure in the lungs (pulmonary hypertension) to see how starting specific lung blood vessel medicines affects outcomes. It may help improve how clinicians choose and monitor treatment over time.
LeuvenAges 1 week+
Hear when a new Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pulmonary arterial hypertension (pah) (who group 1 ph)?
- Yes. Clin2 currently lists 28 recruiting pulmonary arterial hypertension (pah) (who group 1 ph) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pulmonary arterial hypertension (pah) (who group 1 ph) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pulmonary arterial hypertension (pah) (who group 1 ph) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.